Literature DB >> 23261978

Gene transfer for congestive heart failure: update 2013.

Tong Tang1, H Kirk Hammond.   

Abstract

Congestive heart failure is a major cause of morbidity and mortality with increasing social and economic costs. There have been no new high impact therapeutic agents for this devastating disease for more than a decade. However, many pivotal regulators of cardiac function have been identified using cardiac-directed transgene expression and gene deletion in preclinical studies. Some of these increase function of the failing heart. Altering the expression of these pivotal regulators using gene transfer is now either being tested in clinical gene transfer trials, or soon will be. In this review, we summarize recent progress in cardiac gene transfer for clinical congestive heart failure.
Copyright © 2013 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23261978      PMCID: PMC3602385          DOI: 10.1016/j.trsl.2012.11.004

Source DB:  PubMed          Journal:  Transl Res        ISSN: 1878-1810            Impact factor:   7.012


  98 in total

1.  AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells.

Authors:  Federico Mingozzi; Janneke J Meulenberg; Daniel J Hui; Etiena Basner-Tschakarjan; Nicole C Hasbrouck; Shyrie A Edmonson; Natalie A Hutnick; Michael R Betts; John J Kastelein; Erik S Stroes; Katherine A High
Journal:  Blood       Date:  2009-06-08       Impact factor: 22.113

Review 2.  Designing heart performance by gene transfer.

Authors:  Jennifer Davis; Margaret V Westfall; Dewayne Townsend; Michael Blankinship; Todd J Herron; Guadalupe Guerrero-Serna; Wang Wang; Eric Devaney; Joseph M Metzger
Journal:  Physiol Rev       Date:  2008-10       Impact factor: 37.312

3.  Adenylyl cyclase type VI increases Akt activity and phospholamban phosphorylation in cardiac myocytes.

Authors:  Mei Hua Gao; Tong Tang; Tracy Guo; Atsushi Miyanohara; Toshitaka Yajima; Kersi Pestonjamasp; James R Feramisco; H Kirk Hammond
Journal:  J Biol Chem       Date:  2008-10-05       Impact factor: 5.157

4.  Activation of cardiac adenylyl cyclase expression increases function of the failing ischemic heart in mice.

Authors:  N Chin Lai; Tong Tang; Mei Hua Gao; Miho Saito; Toshiyuki Takahashi; David M Roth; H Kirk Hammond
Journal:  J Am Coll Cardiol       Date:  2008-04-15       Impact factor: 24.094

5.  Myocardial adeno-associated virus serotype 6-betaARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure.

Authors:  Giuseppe Rengo; Anastasios Lymperopoulos; Carmela Zincarelli; Maria Donniacuo; Stephen Soltys; Joseph E Rabinowitz; Walter J Koch
Journal:  Circulation       Date:  2008-12-22       Impact factor: 29.690

6.  G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure.

Authors:  Philip W Raake; Leif E Vinge; Erhe Gao; Matthieu Boucher; Giuseppe Rengo; Xiongwen Chen; Brent R DeGeorge; Scot Matkovich; Steven R Houser; Patrick Most; Andrea D Eckhart; Gerald W Dorn; Walter J Koch
Journal:  Circ Res       Date:  2008-07-17       Impact factor: 17.367

Review 7.  Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents.

Authors:  G Minniti; R Muni; G Lanzetta; P Marchetti; R Maurizi Enrici
Journal:  Anticancer Res       Date:  2009-12       Impact factor: 2.480

8.  Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals.

Authors:  M J Byrne; J M Power; A Preovolos; J A Mariani; R J Hajjar; D M Kaye
Journal:  Gene Ther       Date:  2008-07-24       Impact factor: 5.250

Review 9.  In vivo gene regulation using tetracycline-regulatable systems.

Authors:  Knut Stieger; Brahim Belbellaa; Caroline Le Guiner; Philippe Moullier; Fabienne Rolling
Journal:  Adv Drug Deliv Rev       Date:  2009-04-23       Impact factor: 15.470

10.  Rapamycin fed late in life extends lifespan in genetically heterogeneous mice.

Authors:  David E Harrison; Randy Strong; Zelton Dave Sharp; James F Nelson; Clinton M Astle; Kevin Flurkey; Nancy L Nadon; J Erby Wilkinson; Krystyna Frenkel; Christy S Carter; Marco Pahor; Martin A Javors; Elizabeth Fernandez; Richard A Miller
Journal:  Nature       Date:  2009-07-08       Impact factor: 49.962

View more
  3 in total

Review 1.  Cyclic AMP synthesis and hydrolysis in the normal and failing heart.

Authors:  Aziz Guellich; Hind Mehel; Rodolphe Fischmeister
Journal:  Pflugers Arch       Date:  2014-04-24       Impact factor: 3.657

2.  The myeloid-binding peptide adenoviral vector enables multi-organ vascular endothelial gene targeting.

Authors:  Zhi Hong Lu; Sergey Kaliberov; Jingzhu Zhang; Barbara Muz; Abdel K Azab; Rebecca E Sohn; Lyudmila Kaliberova; Yingqiu Du; David T Curiel; Jeffrey M Arbeit
Journal:  Lab Invest       Date:  2014-06-23       Impact factor: 5.662

3.  The type VI adenylyl cyclase protects cardiomyocytes from β-adrenergic stress by a PKA/STAT3-dependent pathway.

Authors:  Yu-Shuo Wu; Chien-Chang Chen; Chen-Li Chien; Hsing-Lin Lai; Si-Tse Jiang; Yong-Cyuan Chen; Lin-Ping Lai; Wei-Fan Hsiao; Wen-Pin Chen; Yijuang Chern
Journal:  J Biomed Sci       Date:  2017-09-04       Impact factor: 8.410

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.